Diagnostic company Hologic has filed a complaint against Fujifilm for allegedly infringing its patents covering a breast imaging system.
The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.
The US Court of Appeals for the Federal Circuit has vacated and remanded the Patent Trial and Appeal Board’s decision to invalidate a foetal testing patent.
American Chemical Society, a scientific society, has taken on nearly 100 alleged counterfeiters accused of creating two pirate sites and sharing the society’s scientific articles.
The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.
The governor of Massachusetts has revealed a legislative proposal aimed at providing up to $500 million over the next five years in the life sciences sector.
Biopharmaceutical company Omeros has filed a complaint against Sandoz for allegedly infringing its patent covering Omidria.
Earlier this month, the US Supreme Court handed down its decision in the biosimilars battle between Amgen and Sandoz, centring on the Biologics Price Competition and Innovation Act.
GSK has won a patent case against Teva in which the company will receive $235 million in damages.
“There’s one stick with this carrot—the whistleblower protection law,” explained Anne Elise Li, IP counsel at Crowell & Moring, in reference to the Defend Trade Secrets Act.